Alleh Lindquist

Alleh Lindquist is the Co-Founder and Chief Executive Officer of FloraWorks, a leading company in the cannabinoid industry. With a passion for the hemp and cannabis sectors, Alleh has spearheaded FloraWorks' mission to develop high-quality, cannabinoid-based therapeutics. Under his leadership, the company has focused on innovative research and the development of rare and novel cannabinoids, such as their flagship product TruCBNTM, which has shown promise in promoting better sleep through rigorous clinical trials. FloraWorks has completed a 1,020-person randomized, double-blind, placebo-controlled clinical trial and built a full GLP toxicology and genotoxicity package for its lead cannabinoid ingredient. FloraWorks is collaborating with advocacy groups, companies, and ACOs to develop a product-agnostic implementation layer for CMS program participation — structured patient intake, physician-guided dosing, drug interaction screening, real-world evidence tracking, and cost-effectiveness documentation — so ACOs can easily choose to participate and select viable products from qualifying suppliers.